Progress, Potential, and Possibilities Podcast / Show Daniel Schmitt - President & CEO, Actuate Therapeutics - Targeting Hard-To-Treat Cancers
Daniel Schmitt is President & Chief Executive Officer of Actuate Therapeutics, Inc. ( https://actuatetherapeutics.com/ ), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β).
Mr. Schmitt brings over 30 years of successful industry experience in operations management, new product development, and business development, having held senior executive positions in both large pharmaceutical and small biotechnology companies, including Fujisawa, Searle / Pharmacia, and Ilex Oncology. During his career, Daniel has led and contributed to the successful development and launch of multiple pharmaceutical products, and has constructed and executed numerous high value licensing, acquisition, and development deals for biotech and pharmaceutical companies, totaling nearly $1 billion in upfront and potential milestone payments.
Mr. Schmitt received his M.B.A and a B.S. in Chemistry from West Virginia University, and has held research positions affiliated with the National Foundation for Cancer Research and at the University of North Carolina School of Medicine. He has served as an Entrepreneur-in-Residence at Northwestern University, and as an external expert consultant for the University of Chicago and the University of Illinois-Chicago. Mr. Schmitt is also a founding member of Chicago Innovation Mentors.
#ActuateTherapeutics #GlycogenSynthaseKinase3Beta #GSK3β #Oncology #Cancer #Elraglusib #PancreaticDuctalAdenocarcinoma #PDAC #EwingSarcoma #Melanoma #ProgressionFreeSurvival #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research